Cerroni L
Department of Dermatology, Medical University of Graz, Austria.
J Clin Pathol. 2006 Aug;59(8):813-26. doi: 10.1136/jcp.2005.033019.
Diagnosis and differential diagnosis of cutaneous lymphoproliferative disorders is one of the most difficult areas in dermatopathology, and biopsies are often taken to rule out a cutaneous lymphoma in patients with "unclear" or "therapy-resistant" skin lesions. Histopathological features alone often enable a given case to be classified to a diagnostic group (eg, epidermotropic lymphomas), but seldom allow a definitive diagnosis to be made. Performing several biopsies from morphologically different lesions is suggested, especially in patients with suspicion of mycosis fungoides. Immunohistochemistry is often crucial for proper classification of the cases, but in some instances is not helpful (eg, early lesions of mycosis fungoides). Although molecular techniques provide new, powerful tools for diagnosing cutaneous lymphoproliferative disorders, results of molecular methods should always be interpreted with the clinicopathological features, keeping in mind the possibility of false positivity and false negativity. In many cases, a definitive diagnosis can be made only on careful correlation of the clinical with the histopathological, immunophenotypical and molecular features.
皮肤淋巴增殖性疾病的诊断与鉴别诊断是皮肤病理学中最具挑战性的领域之一,对于有“不明”或“治疗抵抗”性皮肤损害的患者,常需进行活检以排除皮肤淋巴瘤。仅依靠组织病理学特征往往能将某一病例归入某一诊断类别(如亲表皮性淋巴瘤),但很少能做出明确诊断。建议从形态学不同的损害处进行多次活检,对于疑似蕈样肉芽肿的患者尤其如此。免疫组化对于病例的正确分类常常至关重要,但在某些情况下并无帮助(如蕈样肉芽肿的早期损害)。尽管分子技术为诊断皮肤淋巴增殖性疾病提供了新的有力工具,但分子方法的结果应始终结合临床病理特征进行解读,同时要牢记假阳性和假阴性的可能性。在许多情况下,只有通过仔细关联临床、组织病理学、免疫表型和分子特征才能做出明确诊断。